Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Open Access
- 18 November 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 105 (46), 17908-17912
- https://doi.org/10.1073/pnas.0803725105
Abstract
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months (P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy (P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms (P < 0.001), reduced skin prick test reactivity (P < 0.001), decreased specific serum IgE (P < 0.001), caused fewer adverse events than s.c. immunotherapy (P = 0.001), enhanced compliance (P < 0.001), and was less painful than venous puncture (P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaquesJournal of Medical Virology, 2007
- Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the Third National Health and Nutrition Examination SurveyJournal of Allergy and Clinical Immunology, 2005
- Direct intralymphatic injection of peptide vaccines enhances immunogenicityEuropean Journal of Immunology, 2005
- Durchführung des nasalen Provokationstests bei Erkrankungen der oberen AtemwegeLaryngo-Rhino-Otologie, 2003
- “ARIA”: Global guidelines and new forms of allergen immunotherapyJournal of Allergy and Clinical Immunology, 2001
- Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study.Clinical and Experimental Allergy, 2001
- The Effect of Route of Immunization on Mucosal Immunity and ProtectionThe Journal of Infectious Diseases, 1999
- Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid OrgansScience, 1995
- The Hymenoptera venom study III: Safety of venom immunotherapy2Journal of Allergy and Clinical Immunology, 1990
- The localization of sensory nerve fibers and receptor binding sites for sensory neuropeptides in canine mesenteric lymph nodesPeptides, 1988